For years, most modern weight-loss medicines have worked by helping people feel less hungry.
By reducing appetite, these drugs can lead to substantial weight loss and better blood sugar control. However, scientists are now testing a completely different strategy that may help people burn more energy without changing how much they want to eat.
Researchers from Karolinska Institutet and Stockholm University have developed an experimental tablet that could help treat both obesity and type 2 diabetes. Their findings were published in the scientific journal Cell and have attracted attention because the drug appears to improve metabolism in a unique way.
Obesity and type 2 diabetes are among the fastest-growing health problems worldwide. Millions of people struggle with excess weight, high blood sugar, and related conditions such as heart disease, kidney disease, and fatty liver disease. Doctors and researchers continue to search for treatments that are effective, safe, and easy for patients to use.
Recent years have seen tremendous success with GLP-1 medicines. These drugs help people lose weight by slowing digestion and sending signals to the brain that reduce hunger. While effective, they are usually given by injection and may cause side effects such as nausea, vomiting, and digestive discomfort. Some patients also lose muscle along with fat.
The new treatment aims to solve these problems by targeting a different part of the body. Instead of focusing on the brain and digestive system, it works directly on skeletal muscle. Researchers describe skeletal muscle as an important metabolic organ because it uses large amounts of energy and helps regulate blood sugar.
The scientists designed a special molecule that activates muscle metabolism. The compound belongs to a family called beta-2 agonists, but it has been modified to avoid some of the heart-related side effects that have limited similar drugs in the past.
When tested in animals, the treatment produced several promising results. The animals burned more fat, controlled blood sugar more effectively, and maintained their muscle mass. Researchers also reported that the treatment did not reduce appetite, suggesting that the weight changes were caused by increased energy use rather than eating less food.
These findings are important because muscle preservation has become an increasingly recognized goal in obesity treatment. Muscle helps people stay active, maintain balance, and support healthy metabolism. Losing too much muscle during weight loss can reduce physical function and may make long-term health outcomes less favorable.
To see whether the treatment appeared safe in humans, the researchers conducted a Phase I clinical study involving healthy volunteers and people with type 2 diabetes. A total of 73 participants took part. The researchers reported that the medication was generally well tolerated.
Professor Tore Bengtsson explained that maintaining muscle mass is particularly important because muscle health is strongly linked to overall health and lifespan. Healthy muscles help the body process glucose and may reduce the risk of complications associated with diabetes and obesity.
Assistant Professor Shane C. Wright from Karolinska Institutet described the treatment as a completely new type of therapy. Because it comes as a pill rather than an injection, it may offer greater convenience for patients if future studies prove successful.
Researchers also see potential for combination therapy. Since the new drug works differently from GLP-1 medications, doctors may eventually be able to prescribe both treatments together.
One drug could help regulate appetite, while the other could increase energy use in muscles. This combination might produce stronger results than either treatment alone.
The next phase of development will involve larger studies led by the biotechnology company Atrogi AB. These trials will test whether the promising findings seen in animals and early human studies can be repeated in larger groups of patients.
The project involved international collaboration among scientists from Sweden, Denmark, Australia, and other countries. Funding came from several research organizations dedicated to improving treatments for metabolic diseases.
Although the findings are exciting, caution is still needed. Early-stage studies often produce encouraging results that later research may not fully confirm.
The current evidence shows that the treatment appears safe and biologically active, but researchers still need to demonstrate that it produces meaningful long-term improvements in patients with obesity and diabetes.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies about a simple path to weight loss, and results showing a non-invasive treatment for obesity and diabetes.
Source: Karolinska Institutet.
